

Raffles Medical Group

2007: Room for growth

Raffles Medical Group (RMG) reported a net profit of S\$35.9m, higher than our forecast of S\$32.4m. The variance is mainly due to a write-back of S\$2.3m for deferred tax previously provided for the fair value gain of S\$12.5m from its 50% stake in CapitalLand-Raffles Properties Pte Ltd.

Steady expansion at Raffles Hospital. Revenue from Hospital Services grew 34.6% to S\$99m. RMG hired 12 full-time consultant specialists in 2007, bringing the total to 50. Revenue intensity improved due to more high complexity cases such as spinal surgeries, neural surgeries, fertility treatments and increased usage of neo-natal intensive care units (ICU). Besides patients from this region, RMG is increasingly seeing patients from outside Asia such as Russia, the US and Europe. EBIT margin for Hospital Services was maintained at 20%. Benefits from economies of scale at Raffles Hospital were offset by the need to adjust remuneration for doctors and nurses due to a tight labour market.

Healthcare Services focuses on corporate market. Revenue from Healthcare Services grew 14.8% to S\$69.7m. The buoyant economic environment resulted in more hiring and increased patient volume at its network of family medicine clinics. RMG made further inroads into the corporate market by setting up three clinics at Science Park (Ayer Rajah), TechPark and TechPlace (Ang Mo Kio). However, new centres usually take six to 12 months to break even. This resulted in a lower EBIT margin of 9.1% in 2007 compared with the 11.9% in the previous year. Management expects the situation to normalise in 2008 as the new centres start to contribute more significantly.

Improved operating efficiency at Raffles Hospital. RMG's flagship Raffles Hospital delivers medical care through its unique Group Practice Model. Raffles Hospital plans to add another 50 beds in 2008, bringing the total to 250 beds. The recruitment of more specialists has increased revenue intensity. Higher throughput of patients will provide economies of scale, improved operating efficiency and better margins from the Hospital Services business.

Further expansion at Changi International Airport. RMG's contract to provide medical services at Changi International Airport was renewed for another five years. The company has a new 24-hour medical centre with multi-disciplinary services in family medicine, health screening, occupational medicine, aesthetics, dentistry, obstetrics & gynaecology and emergency services at the new Terminal 3. RMG currently operates seven clinics in the entire airport complex. RMG plans to add another five clinics on a group-wide basis in 2008.

Maintain BUY. We like RMG for the growth momentum at Raffles Hospital. Raffles Hospital will benefit from the influx of foreign patients, increase in revenue intensity and positive impact from economies of scale. We raised our target price to S\$2.33 based on our three-stage discounted cash flow model.

SINGAPORE

Raffles Medical Group

BUY

Current Price: S\$1.37

Target Price: S\$2.33

(Previous: S\$2.10)

Jonathan Koh

☎ (65) 6539 1026

jonathankoh@uobkayhian.com

Sector	Healthcare
Bloomberg	RFMG SP
Website	www.raflmesmedical.com

52-Wk Avg Daily Vol. ('000)	438
Market Cap (S\$m)	706.2
(US\$m)	498.1

Book NTA per Share (S\$)	0.39
ROE (%)	22.9
Net Debt per Share (S\$)	0.01

Results Due	
Interim	July
Final	February

12-Month House Call Tracking

Date	Rec	Target Price (S\$)
19/02/08	BUY	2.33
29/10/07	BUY	2.10
23/10/07	BUY	2.05


Price Chart



Year to 31 Dec	Turnover (S\$m)	EBITDA (S\$m)	Net Profit (S\$m)	EPS (S¢)	EPS Growth (%)	PE (x)	EV/EBITDA (x)	DPS* (S¢)
2006	134.2	22.6	15.7	3.5	27.9	39.1	31.5	2.3
2007	168.7	32.4	35.9	7.4	110.3	18.6	21.9	2.5
2008F	201.4	47.2	31.4	6.1	(17.3)	22.5	15.1	3.0
2009F	255.4	58.2	40.0	7.8	27.5	17.6	12.2	3.5
2010F	288.8	68.4	48.1	9.3	20.1	14.7	10.4	4.5

2007 earnings include fair value gain of S\$12.5m from 50% stake in CapitalLand-Raffles Properties Pte Ltd
* Excludes special dividend 1.36¢ for FY06

Sales By Business (FY07)



Source: RMG

Profit & Loss

Year to 31 Dec (\$m)	2006	2007	2008F	2009F	2010F
Turnover	134.2	168.7	201.4	255.4	288.8
EBITDA	22.6	32.4	47.2	58.2	68.4
Pre-tax Profit	20.0	41.4	39.2	50.0	60.1
Net Profit	15.7	35.9	31.4	40.0	48.1
EPS (cents)	3.5	7.4	6.1	7.8	9.3

Balance Sheet

Year to 31 Dec (\$m)	2006	2007	2008F	2009F	2010F
Current Assets	76.4	44.5	72.6	87.8	120.8
Total Assets	151.8	335.4	308.6	322.4	355.1
Current Liabilities	37.9	79.7	50.8	62.6	70.3
Long-Term Loans	0.0	0.0	40.0	20.0	20.0
Shareholders' Funds	112.9	200.8	216.7	238.7	263.6
Total Equity & Liabilities	151.8	281.5	308.6	322.4	355.1

Cash Flow

Year to 31 Dec (\$m)	2006	2007	2008F	2009F	2010F
Operating	19.7	40.1	31.1	51.5	57.1
Investing	(1.9)	(52.8)	(5.0)	(5.0)	(5.0)
Financing	(10.7)	(9.2)	1.3	(38.0)	(23.2)
Net Cash In/(Out) Flow	7.1	(22.0)	27.3	8.5	29.0
Begin Cash & Cash Equiv.	34.8	41.8	19.7	47.1	55.6
End'g Cash & Cash Equiv.	41.8	19.7	47.1	55.6	84.5

We have based this document on information obtained from sources we believe to be reliable, but we do not make any representation or warranty nor accept any responsibility or liability as to its accuracy, completeness or correctness. Expressions of opinion contained herein are those of UOB Kay Hian Research Pte Ltd only and are subject to change without notice. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of the addressee only and is not to be taken as substitution for the exercise of judgement by the addressee. This document is not and should not be construed as an offer or a solicitation of an offer to purchase or subscribe or sell any securities. UOB Kay Hian and its affiliates, their Directors, officers and/or employees may own or have positions in any securities mentioned herein or any securities related thereto and may from time to time add to or dispose of any such securities. UOB Kay Hian and its affiliates may act as market maker or have assumed an underwriting position in the securities of companies discussed herein (or investments related thereto) and may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or underwriting services for or relating to those companies.

UOB Kay Hian (U.K.) Limited, a UOB Kay Hian subsidiary which distributes UOB Kay Hian research for only institutional clients, is an authorised person in the meaning of the Financial Services and Markets Act 2000 and is regulated by The Securities and Futures Authority.

In the United States of America, this research report is being distributed by UOB Kay Hian (U.S.) Inc ("UOBKHUS") which accepts responsibility for the contents. UOBKHUS is a broker-dealer registered with the U.S. Securities and Exchange Commission and is an affiliate company of UOBKH. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact UOBKHUS, not its affiliate. The information herein has been obtained from, and any opinions herein are based upon sources believed reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All opinions and estimates herein reflect our judgement on the date of this report and are subject to change without notice. This report is not intended to be an offer, or the solicitation of any offer, to buy or sell the securities referred to herein. From time to time, the firm preparing this report or its affiliates or the principals or employees of such firm or its affiliates may have a position in the securities referred to herein or hold options, warrants or rights with respect thereto or other securities of such issuers and may make a market or otherwise act as principal in transactions in any of these securities. Any such non-U.S. persons may have purchased securities referred to herein for their own account in advance of release of this report. Further information on the securities referred to herein may be obtained from UOBKHUS upon request.

<http://research.uobkayhian.com>

MICA (P) 017/05/2007
RCB Regn. No. 198700235E